IGI Logo

IPM growth on an uptrend, led by select therapies

Aug’21: IPM growth strengthens on monthly basis

* IPM growth was 17.7% YoY in Aug’21 v/s 13.7 % YoY in Jul’21.

* Respiratory/Analgesics/Anti-Infectives grew 38.2%/32.4%/29.2% YoY.

* Respiratory sales growth increased sequentially, with 38.2% YoY growth achieved in Aug’21 (v/s 22.8% YoY growth in Jul’21).

For quarter ended Aug’21: Volume/Price/NP drive IPM growth

* For the quarter ended Aug’21, YoY growth stood at 15.2% YoY.

* Price growth of 5.8% YoY and New Product growth of 3.5% YoY was further boosted by 5.9% YoY volume growth.

Ipca, Aristo, FDC, and Ajanta – top performers for Aug’21

* Among the top 30 corporates, Ipca (+38.5% YoY), Aristo (+34% YoY), FDC (+33.6 % YoY), Indoco Remedies (+33% YoY), Ajanta (31.7% YoY), Macleods (+28.8% YoY), and Mankind (+27.1% YoY) delivered better-than-IPM growth. With a lower number of COVID cases, Glenmark’s sales declined 17% YoY in Aug’21.

* Ipca posted a strong offtake of products (Zerodol franchise) in the Pain segment (~32% of sales; up 46% YoY), which grew 46% YoY.

* Ajanta saw broad-based growth across therapies driving overall YoY growth.

* Cadila and Cipla showed lower-than-industry growth in Aug’21 (11.9%/12.6% YoY) v/s +8.8%/+5.7% YoY in Jul’21.

* On a MAT basis, Merck/Ipca/Ajanta/Alkem reported the highest volume growth (+15.6%/14.3%/11.9%/10.9% YoY). Glenmark posted the highest growth in new launches (+26.1% YoY).

On MAT basis, Anti-Infectives, VMN, Gastro, and Pain/Analgesics drive YoY growth

* On a MAT basis, industry growth came in at 14.5% YoY.

* Anti-Infectives/VMN/Gastro grew 25.4%/21.6%/20% YoY

* Anti-Malarials sales declined 4.6% YoY, impacting overall growth.

* While Respiratory posted strong YoY growth in May, June, July, and Aug’21, it remained a drag on YoY growth on a MAT basis.

Cardio/Diabetes therapy growth showing no signs of revival

* Cardiology/Diabetes grew at a moderate rate of 1.2%/5.2% YoY for Aug’21. Experts indicate fewer patient follow-ups and the smaller total patient pool are due to patients who succumbed to COVID being comorbid and diabetic/cardiac patients.

* The new diagnosis in Diabetes for COVID-induced patients and the normalization of the patient-doctor connect would revive growth in the Cardio/Diabetes therapy over the near-to-medium term.

To Read Complete Report & Disclaimer Click Here

For More Motilal Oswal Securities Ltd Disclaimer http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html SEBI Registration number is INH000000412

Above views are of the author and not of the website kindly read disclaimer